Inari Medical, Inc. ((NARI)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The PERSEVERE Study, officially titled the same, is a clinical trial conducted by Inari Medical, Inc. aimed at evaluating the effectiveness of the FlowTriever System compared to the standard of care in treating high-risk pulmonary embolism. This study is significant as it seeks to provide insights into potentially more effective treatment options for this serious condition.
Intervention/Treatment: The study tests two interventions: the FlowTriever System, a mechanical thrombectomy device, and the standard of care procedure. The FlowTriever System is designed to remove blood clots from the pulmonary arteries, potentially offering a more efficient treatment method.
Study Design: This is an interventional study with a randomized allocation and a parallel intervention model. There is no masking involved, meaning both the participants and researchers know which treatment is being administered. The primary purpose of the study is treatment-focused.
Study Timeline: The study began on December 16, 2024, with its primary completion and estimated overall completion dates yet to be announced. The most recent update was submitted on July 14, 2025, indicating ongoing recruitment and progress.
Market Implications: The ongoing recruitment and updates from the PERSEVERE Study could positively influence Inari Medical’s stock performance by showcasing their commitment to advancing treatment options for pulmonary embolism. Successful outcomes could enhance investor sentiment and position Inari Medical favorably against competitors in the medical device industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.